Under the terms of the agreement, Sarepta Theraputics will retain an exclusive option to license the program and will assist with research. Initial trials of the program will take place at Nationwide Children’s in late 2017.
“Given the complexities of Duchenne Muscular Dystrophy, we know that it is going to require multiple treatment approaches,” said Edward Kaye, CEO of Sarepta Therapeutics. “With that goal in mind, we are excited to support clinical development for Nationwide’s gene therapy program with the goal to help all boys with DMD.”
More articles on transactions and valuations:
3 New Hampshire hospitals complete affiliation to form GraniteOne Health
FTC speaks out against Wellmont, MSHA merger again 1 week before decision
17 recent hospital transactions and partnerships
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
